| Identification | More | [Name]
Imidapril | [CAS]
89371-37-9 | [Synonyms]
IMIDAPRIL
(s)-3-(n-((s)-1-ethoxycarbonyl-3-phenylpropyl)-l-alanyl)-1-methyl-2-oxoimidazoline-4-carboxylic acid
lmidaprfil
(4S)-3-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic Aci
4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, (4S)-
4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3[R*(R*)],4R*]]-
(4S)-3-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic Acid Hydrochloride
(4S)-3-[(2S)-2-[N-[(1S)-1-(Ethyoxycarbonyl)-3-phenylpropyl]amino]propionyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
(4S)-3-[(2S)-2-[[(1S)-1-Ethoxycarbonyl-3-phenylpropyl]amino]propionyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid
(4S)-3-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
(S,S,S)-Imidapril
Imidapril HCl | [Molecular Formula]
C20H27N3O6 | [MDL Number]
MFCD00870777 | [Molecular Weight]
405.44 | [MOL File]
89371-37-9.mol |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
195-197°C | [alpha ]
D20 -71.7° (c = 0.5 in ethanol) | [Boiling point ]
577.0±60.0 °C(Predicted) | [density ]
1.266±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [form ]
Solid | [pka]
2.44±0.20(Predicted) | [color ]
White to off-white | [Usage]
Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive | [CAS DataBase Reference]
89371-37-9(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Imidapril is a new ACE inhibitor launched in Japan as a once-daily therapy for
hypertension. Its active metabolite has more potent inhibitory effects on all tissue ACES from
spontaneously hypertensive rats (SHRs) and Wistar Kyoto rats (WKYs) than many other ACE
inhibitors including enalapril and captopril. It has a very long duration of action. In strokeprone
spontaneously hypertensive rats (SHRSP), imidapril is effective in stroke prevention at
a considerably lower dose than enalapril. This stroke preventive effect has been suggested to
be primarily by an indirect mechanism related to the amelioration of kidney dysfunction. | [Chemical Properties]
White Solid | [Originator]
Tanabe (Japan) | [Uses]
Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive | [Definition]
ChEBI: Imidapril is a member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure. It has a role as an antihypertensive agent, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and a prodrug. It is a dipeptide, a member of imidazolidines, a dicarboxylic acid monoester, a secondary amino compound, an ethyl ester and a N-acylurea. | [Brand name]
Tanatril; Novarok |
|
|